Patricia Garrido Castro

Title: Patricia Garrido Castro: Innovator in Immunotherapy

Introduction

Patricia Garrido Castro is a prominent inventor based in Utrecht, Netherlands. She has made significant contributions to the field of immunotherapy, particularly through her innovative work on monoclonal antibodies. Her research focuses on enhancing the efficacy of treatments for various cancers.

Latest Patents

Patricia holds a patent for "Monoclonal antibodies directed against programmed death-1 protein and their use in medicine." This patent describes antibodies that bind to the immune checkpoint protein programmed death-1 (PD-1), which plays a crucial role in regulating immune responses. The antibodies are designed with modifications in the Fc region to eliminate or reduce Fc-mediated effector functions. This innovation has potential applications in immunotherapy, particularly for cancer treatment.

Career Highlights

Throughout her career, Patricia has worked with leading companies in the biotechnology sector, including BioNTech SE and Genmab A/S. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in the field of medicine.

Collaborations

Patricia has collaborated with notable professionals in her field, including Ugur Sahin and Sina Fellermeier-Kopf. These collaborations have further enriched her research and expanded the impact of her innovations.

Conclusion

Patricia Garrido Castro is a trailblazer in the field of immunotherapy, with her patent on monoclonal antibodies showcasing her commitment to advancing medical science. Her work continues to inspire and pave the way for future innovations in cancer treatment.